The Aortic Valve Diseases drugs in development market research report provides comprehensive information on the therapeutics under development for Aortic Valve Diseases, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Aortic Valve Diseases. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Aortic Valve Diseases and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Aortic Valve Diseases by six companies/universities/institutes. The top development phase for Aortic Valve Diseases is phase ii with three drugs in that stage. The Aortic Valve Diseases pipeline has six drugs in development by companies and one by universities/ institutes. Some of the companies in the Aortic Valve Diseases pipeline products market are: REDNVIA, Spark Biopharma and Rancho Santa Fe Bio.
The key targets in the Aortic Valve Diseases pipeline products market include Dipeptidyl Peptidase 4, Apolipoprotein A, and High Mobility Group Protein B1.
The key mechanisms of action in the Aortic Valve Diseases pipeline product include Dipeptidyl Peptidase 4 Inhibitor with two drugs in Phase III. The Aortic Valve Diseases pipeline products include two routes of administration with the top ROA being Oral and two key molecule types in the Aortic Valve Diseases pipeline products market including Small Molecule, and Antisense Oligonucleotide.
Aortic Valve Diseases overview
Aortic Valve Disease (AVD) is a type of valve disease where hearts aortic valve does not work properly. Aortic valve controls the flow of blood from heart to all the body parts. When there is a damage to the aortic valve blood flow is affected. The 2 main aortic valve diseases are aortic stenosis and aortic regurgitation. In aortic stenosis blood flow is restricted as the valve gets narrowed while in regurgitation leakage of blood back to the heart occurs. It can be congenital or can develop later in life. Aging, underlying diseases, aortic dissection, trauma, senile aortic calcification, bicuspid aortic valve are the common causes and symptoms are chest pain, SOB, dizziness, irregular heartbeat, loss of appetite, weight gain. Diagnosed by 2D echo, ECG, chest X-ray, MRI and sometimes cardiac catherization done. Mild cases of AVD does not need any treatment. Mild to moderate require symptomatic treatment and preventive measures. Surgical procedures to replace the damaged aortic valve.
For a complete picture of Aortic Valve Diseases’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
